June 14, 2012

HELIX BIOPHARMA CORP. ANNOUNCES Q3 2012 RESULTS AND ACTIONS TAKEN BY ITS NEW BOARD (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE MKT, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced its financial results and research and development update for the quarter ended April 30, 2012 and actions taken by its reconstituted Board of Directors (the “New Board”).